← Leaderboards
Sam C. Wang
University Of California, San Francisco
$4,494,981
Attributed
$5,166,556
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,166,556 · 4
By mechanism
R37$2,914,814 · 1
R01$1,343,150 · 1
K08$803,960 · 1
F32$104,632 · 1
Top collaborators
- Tae Hyun Hwang2 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Gabriel Chamie$8,918,315
- Min Hee Kim$741,419
- Melissa Quino Reeves$451,200
- Bryan R Greenhouse$13,581,963
- Harold A Chapman$29,865,601
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSamplingMolecularGenomicsResearch PersonnelIn VivoMultidisciplinaryProtein ExpressionCellsTumorPhenotypeGenesCharacteristicsLifeIn VitroHeterogeneityInnovationCancer PatientGeneticMalignant Stomach NeoplasmClinically ActionableMissionPublic HealthUnited States National Institutes Of Health
Grant awards (15)
Using artificial intelligence to discover spatial, genomic, and pathologic biomarkers to guide and augment immune checkpoint inhibitor therapy for gastric cancer$665,617
R01 · FY2025 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$660,170
R37 · FY2025 · CA · contact PI
Using artificial intelligence to discover spatial, genomic, and pathologic biomarkers to guide and augment immune checkpoint inhibitor therapy for gastric cancer$677,533
R01 · FY2024 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$627,162
R37 · FY2024 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$209,772
R37 · FY2024 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$652,162
R37 · FY2023 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$62,937
R37 · FY2023 · CA · contact PI
Determining the role of germline CDH1 variants in gastric cancer outcome disparities in Hispanic/Latino patients$702,611
R37 · FY2022 · CA · contact PI
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation$160,920
K08 · FY2022 · CA · contact PI
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation$160,920
K08 · FY2021 · CA · contact PI
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation$160,920
K08 · FY2020 · CA · contact PI
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation$160,680
K08 · FY2019 · CA · contact PI
Arid1a loss accelerates pancreatic ductal adenocarcinoma precursor formation$160,520
K08 · FY2018 · CA · contact PI
Defining the Contributions of Pancreatic Ductal and Acinar Cells to Tumorigenesis$53,354
F32 · FY2009 · CA · contact PI
Defining the Contributions of Pancreatic Ductal and Acinar Cells to Tumorigenesis$51,278
F32 · FY2008 · CA · contact PI